Subphenotypic Classification of Immune Response in Sepsis: Predicting Mortality and Guiding Future Personalized Immunotherapy
Keywords:
sepsis, macrophage activation-like syndrome, immunoparalysis, immune response, macrophage activation syndrome, immunosuppression, subphenotypeAbstract
The most recent definition of sepsis highlights the dysregulation of the host’s immune response to infection, which varies between individual hosts, with patients predominantly presenting with either hyperinflammation, immunoparalysis, or a combination of both states. Therefore, management strategies must be tailored to accommodate the heterogeneity of patients with sepsis, as these conditions are associated with distinct prognoses and therapeutic approaches. Identification of the immune response in patients with sepsis can be achieved through advanced techniques, such as gene expression profiling or, more simply, through a subphenotypic approach. This article introduces a subphenotypic classification of the sepsis immune response into macrophage activation-like syndrome (MALS), where pathological macrophage activation leads to excessive hyperinflammation, immunoparalysis, or neither. Patients are classified using serum ferritin levels and monocyte HLA-DR expression, which is assessed using peripheral blood. This classification demonstrates significant differences in survival across groups, which is attributed to their distinct underlying biological processes. Immunotherapeutic options also differ for these three groups. In the future, such immune response classifications will be valuable in sepsis management algorithms for personalized prognostication and therapy.References
Purba AKR, Mariana N, Aliska G, et al. The burden and costs of sepsis and reimbursement of its treatment in a developing country: An observational study on focal infections in Indonesia. Int J Infect Dis. 2020;96:211-8.
World Health Organization. Global report on the epidemiology and burden of sepsis: current evidence, identifying gaps and future directions. Geneva: World Health Organization; 2020.
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-10.
Ding R, Meng Y, Ma X. The central role of the inflammatory response in understanding the heterogeneity of Sepsis-3. Biomed Res Int. 2018;5086516.
Chen J, Wei H. Immune intervention in sepsis. Frontiers Pharmacol. 2021;12.
Davenport EE, Burnham KL, Radhakrishnan J, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med. 2016;4(4):259-71.
Scicluna BP, Vught LAV, Zwinderman AH, et al. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. Lancet Respir Med. 2017;5(10):816-26.
Barichello T, Generoso JS, Singer M, Dal-Pizzol F. Biomarkers for sepsis: more than just fever and leukocytosis—a narrative review. Crit Care. 2022;26:14.
Maria da Gomes Cunha D, Galdino da Silva G, Hamasaki MY. New biomarkers of sepsis with clinical relevance. Clinical management of shock - the science and art of physiological restoration: IntechOpen; 2020.
Sukhbaatar N, Weichhart T. Iron regulation: macrophages in control. Pharmaceuticals (Basel). 2018;11(4):137.
Moreira AC, Mesquita G, Gomes MS. Ferritin: an inflammatory player keeping iron at the core of pathogen-host interactions. Microorganisms. 2020;8(4):589.
Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D’Cruz DP, Shoenfeld Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013;11(185).
Karakike E, Giamarellos-Bourboulis EJ. Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis. Front Immunol. 2019;10(55).
Carter SJ, Tattersall RS, Ramanan AV. Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology. 2018;58(1):5-17.
Kyriazopoulou E, Leventogiannis K, Norrby-Teglund A, et al. Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. BMC Medicine. 2017;15:172.
Anderko RR, Gómez H, Canna SW, et al. Sepsis with liver dysfunction and coagulopathy predicts an inflammatory pattern of macrophage activation. Intensive Care Medicine Experimental. 2022;16:6.
Khare N, Jinkala SR, Kanungo S. Performance of HScore in reactive hemophagocytic lymphohistiocytosis. Indian J Hematol Blood Transfus. 2021;37(2):256-63.
Fardet L, Galicier L, Lambotte O, et al. Development and validation of the H Score, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613-20.
Fauter M, Mainbourg S, El Jammal T, et al. Extreme hyperferritinemia: causes and prognosis. J Clin Med. 2022;11(18):5438.
Berlot G, Passero S. Immunoparalysis in septic shock patients. Infectious process and sepsis: IntechOpen; 2020.
Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862-74.
Bruse N, Leijte GP, Pickkers P, Kox M. New frontiers in precision medicine for sepsis-induced immunoparalysis. Expert Review of Clinical Immunology. 2019;15(3):251-63.
Cassatella MA. Human mature neutrophils as atypical APC. Blood. 2017;129(4):1895-6.
Pfortmueller CA, Meisel C, M MF, Schefold JC. Assessment of immune organ dysfunction in critical illness: Utility of innate immune response markers. Intensive Care Med Exp. 2017;5(1):49.
Joshi I, Carney WP, Rock EP. Utility of monocyte HLA-DR and rationale for therapeutic GM-CSF in sepsis immunoparalysis. Front Immunol.14:1130214.
Quadrini KJ, Patti-Diaz L, Maghsoudlou J, Cuomo J, Hedrick MN, McCloskey TW. A flow cytometric assay for HLA-DR expression on monocytes validated as a biomarker for enrollment in sepsis clinical trials. Cytometry B Clin Cytom. 2021;100:103-14.
Spies C, Luetz A, Lachmann G, et al. Influence of granulocyte-macrophage colony-stimulating factor or Influenza vaccination on HLA-DR, infection and delirium days in immunosuppressed surgical patients: double blind, randomised controlled trial. PLoS One. 2015;10(12):e0144003.
Leventogiannis K, Kyriazopoulou E, Antonakos N, et al. Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial. Cell Rep Med. 2022;3(11):100817.
de Roquetaillade C, Dupuis C, Faivre V, Lukaszewicz AC, Brumpt C, Payen D. Monitoring of circulating monocyte HLA-DR expression in a large cohort of intensive care patients: relation with secondary infections. Ann Intensive Care. 2022;12(39).
Leijte GP, Rimmelé T, Kox M, et al. Monocytic HLA-DR expression kinetics in septic shock patients with different pathogens, sites of infection and adverse outcomes. Critical Care. 2020;24:110.
Kotsaki A, Pickkers P, Bauer M, et al. ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol. BMJ Open. 2022;12:e067251.
Gharamti AA, Samara O, Monzon A, et al. Proinflammatory cytokines levels in sepsis and healthy volunteers, and tumor necrosis factor-alpha associated sepsis mortality: A systematic review and meta-analysis. Cytokine. 2022;158:156006.
Rochwerg B, Oczkowski SJ, Siemieniuk RAC, et al. Corticosteroids in sepsis: an updated systematic review and meta-analysis. Crit Care Med. 2018;46(9):1411-20.
Antonelli M. Sepsis and septic shock: pro-inflammatory or anti-inflammatory state? Journal of Chemotherapy. 1999;11(6):536-40.
Inoue S, Suzuki-Utsunomiya K, Okada Y, et al. Reduction of immunocompetent T cells followed by prolonged lymphopenia in severe sepsis in the elderly. Crit Care Med. 2013;41(3):810-9.
Liu D, Huang SY, Sun JH, et al. Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options. Mil Med Res. 2022;9(1):56.
Lazăr A, Georgescu AM, Vitin A, Azamfirei L. Precision medicine and its role in the treatment of sepsis: a personalised view. J Crit Care Med (Targu Mures). 2019;5(3):90-6.
Slim MA, van Mourik N, Dionne JC, et al. Personalised immunotherapy in sepsis: a scoping review protocol. BMJ Open. 2022;12(5):e060411.
Carcillo JA, Kernan KK, Horvat CM, Simon DW, Aneja RK. Why and how is hyperferritinemic sepsis different from sepsis without hyperferritinemia? Pediatr Crit Care Med. 2020;21(5):509-12.
Steinhagen F, Schmidt SV, Schewe J-C, Peukert K, Klinman DM, Bode C. Immunotherapy in sepsis - brake or accelerate? Pharmacology & Therapeutics. 2020;208:107476.
Davies R, O’Dea K, Gordon A. Immune therapy in sepsis: Are we ready to try again? Journal of the Intensive Care Society. 2018;19(4):326-44.
McBride MA, Patil TK, Bohannon JK, Hernandez A, Sherwood ER, Patil NK. Immune Checkpoints: Novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression. Frontiers in Immunology. 2021;11.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Velma Herwanto, Khie Chen Lie, Robert Sinto, Leonard Nainggolan
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright
The authors who publish in this journal agree to the following requirements:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
